Vivo Capital LLC Raises Position in Rezolute, Inc. (NASDAQ:RZLT)

Vivo Capital LLC increased its stake in Rezolute, Inc. (NASDAQ:RZLT) by 569.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,242,842 shares of the company’s stock after purchasing an additional 2,758,403 shares during the quarter. Vivo Capital LLC owned approximately 8.18% of Rezolute worth $3,219,000 at the end of the most recent quarter.

Separately, Federated Hermes Inc. raised its stake in shares of Rezolute by 53.6% in the fourth quarter. Federated Hermes Inc. now owns 10,154,327 shares of the company’s stock valued at $10,083,000 after buying an additional 3,544,053 shares during the period. Institutional investors own 82.97% of the company’s stock.

Insider Transactions at Rezolute

In other news, CFO Daron Evans purchased 41,900 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was bought at an average cost of $1.30 per share, for a total transaction of $54,470.00. Following the acquisition, the chief financial officer now directly owns 70,900 shares of the company’s stock, valued at approximately $92,170. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Rezolute news, CFO Daron Evans purchased 41,900 shares of Rezolute stock in a transaction that occurred on Friday, February 16th. The shares were bought at an average price of $1.30 per share, for a total transaction of $54,470.00. Following the acquisition, the chief financial officer now directly owns 70,900 shares in the company, valued at $92,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Young-Jin Kim acquired 36,503 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was acquired at an average price of $1.91 per share, with a total value of $69,720.73. Following the acquisition, the director now owns 115,450 shares in the company, valued at approximately $220,509.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 179,403 shares of company stock worth $306,601. Insiders own 20.80% of the company’s stock.

Rezolute Stock Down 0.7 %

Shares of Rezolute stock traded down $0.02 during trading on Thursday, reaching $2.90. The company’s stock had a trading volume of 63,292 shares, compared to its average volume of 300,677. The company has a market cap of $116.38 million, a price-to-earnings ratio of -2.65 and a beta of 1.29. The firm’s 50-day moving average is $2.41 and its two-hundred day moving average is $1.50. Rezolute, Inc. has a 52-week low of $0.72 and a 52-week high of $3.69.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.27). On average, equities research analysts anticipate that Rezolute, Inc. will post -1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on RZLT shares. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Rezolute in a research note on Thursday, March 7th. Jonestrading started coverage on shares of Rezolute in a research note on Thursday, April 18th. They issued a “buy” rating and a $10.00 target price for the company. JMP Securities restated a “market outperform” rating and set a $7.00 price target on shares of Rezolute in a research note on Thursday, April 18th. Finally, Maxim Group initiated coverage on shares of Rezolute in a report on Tuesday, April 9th. They issued a “buy” rating and a $8.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $8.80.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.